Association of TP53 Mutational Status and Survival in Anaplastic Thyroid Cancer Treated with Dabrafenib Plus Trametinib. (PubMed, Eur Thyroid J) - Oct 2, 2026 - "This study suggested that TP53 mutations represent a prognostic factor, associated with worse survival in patients with BRAF p.V600E ATC undergoing DT treatment, highlighting the potential clinical value of incorporating TP53 profiling into patient management."
Journal • Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma • BRAF • TP53
|
|
Ana Saramago; Branca Maria Cavaco; Daniela Cavaco; Miguel Rito; Raquel Dias; Ricardo Rodrigues; Saudade André; Tiago Nunes da Silva; Valeriano Leite
|